1. Clinical & Scientific Overview
Carboplatin (TIP-MED-000560, Reference Code [ONC-11]) is classified under
Oncology & Antineoplastic Medicines as a Platinum Alkylating-Like Agent • Second-Generation Platinum Coordination Complex.
Within the Indian regulatory and compendial framework, it is governed under Schedule H (Prescription Only — Specialist Oncology Supervision).
Paraplatin Reference, Kemocarb (Fresenius Kabi Oncology), Biocarb (Biocon)
Solution for IV Infusion: 150 mg/15 mL, 450 mg/45 mL vials
Oncology Specialisation & Cytotoxic Safety Protocol
Platinum Alkylating-Like Agent
Antineoplastic Cytotoxic
Standard Regimen & Cycle Context: CALVERT FORMULA DOSING (mg, NOT mg/m2): Total Dose (mg) = Target AUC (typically 4–6 mg/mL*min) x [GFR (mL/min) + 25]; cap estimated GFR at 125 mL/min to prevent overdosing in cachectic patients with low serum creatinine.
Signature Dose-Limiting Toxicities & Organ Monitoring: Dose-limiting Thrombocytopenia (nadir Day 14–21) and neutropenia; markedly less nephrotoxic, ototoxic, and emetogenic than cisplatin; cumulative hypersensitivity/anaphylaxis risk peaks around Cycle 6–8 of platinum re-challenge.
Extravasation, Premedication & Safe Cytotoxic Handling: Dilute in 5% Dextrose (D5W — avoid chloride-containing solutions which accelerate degradation in long storage, though short-term 0.9% NaCl is used in some protocols; D5W is standard); always verify Calvert formula calculation with capped CrCl (max 125 mL/min).
3. Mechanism of Action & Pharmacodynamics
Cyclobutane dicarboxylate leaving group hydrolyses more slowly than cisplatin's chloride groups, forming aquated platinum species that cross-link N7-guanine DNA bases (intrastrand and interstrand cross-links).
4. Therapeutic Indications & Evidence-Supported Uses
- Epithelial Ovarian Carcinoma
- Non-Small Cell and Small Cell Lung Cancer
- Triple-Negative Breast, Head & Neck, and Cervical Carcinomas
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Educational Oncology Regimen Context (Specialist Reference Only): CALVERT FORMULA DOSING (mg, NOT mg/m2): Total Dose (mg) = Target AUC (typically 4–6 mg/mL*min) x [GFR (mL/min) + 25]; cap estimated GFR at 125 mL/min to prevent overdosing in cachectic patients with low serum creatinine.
Administration & Meal Timing: CALVERT FORMULA DOSING (mg, NOT mg/m2): Total Dose (mg) = Target AUC (typically 4–6 mg/mL*min) x [GFR (mL/min) + 25]; cap estimated GFR at 125 mL/min to prevent overdosing in cachectic patients with low serum creatinine.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Specialist oncology pharmacokinetic profile; dosing depends on Body Surface Area (BSA in m2), Calvert GFR formula, or flat targeted dosing with strict organ-function adjustments.
Hepatic enzymatic activation/inactivation or proteolytic degradation (for monoclonal antibodies); see specific polymorphism and interaction notes.
Verify serum creatinine and eGFR before every cycle; see drug-specific renal dosing and uroprotection rules.
Check total bilirubin, AST, and ALT prior to each cycle; taxanes, anthracyclines, and TKIs require strict hepatic dose modification.
7. Contraindications, Precautions & High-Risk Warnings
- Severe hypersensitivity to Carboplatin or formulation vehicle
- Pregnancy and lactation (potent teratogen/embryotoxic class warning unless explicitly evaluated by oncology specialist)
- Severe unrecovered bone marrow aplasia or decompensated organ failure per protocol thresholds
Key Clinical Precautions: Dose-limiting Thrombocytopenia (nadir Day 14–21) and neutropenia; markedly less nephrotoxic, ototoxic, and emetogenic than cisplatin; cumulative hypersensitivity/anaphylaxis risk peaks around Cycle 6–8 of platinum re-challenge.
8. Adverse Effects Profile
- Dose-limiting Thrombocytopenia (nadir Day 14–21) and neutropenia; markedly less nephrotoxic, ototoxic, and emetogenic than cisplatin; cumulative hypersensitivity/anaphylaxis risk peaks around Cycle 6–8 of platinum re-challenge.
- Dose-limiting Thrombocytopenia (nadir Day 14–21) and neutropenia; markedly less nephrotoxic, ototoxic, and emetogenic than cisplatin; cumulative hypersensitivity/anaphylaxis risk peaks around Cycle 6–8 of platinum re-challenge.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Dose-limiting Thrombocytopenia (nadir Day 14–21) and neutropenia; markedly less nephrotoxic, ototoxic, and emetogenic than cisplatin; cumulative hypersensitivity/anaphylaxis risk peaks around Cycle 6–8 of platinum re-challenge.
- Avoid live-attenuated vaccines during immunosuppressive chemotherapy; verify CYP3A4, UGT1A1, DPD, and QTc interactions before each cycle.
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Dilute in 5% Dextrose (D5W — avoid chloride-containing solutions which accelerate degradation in long storage, though short-term 0.9% NaCl is used in some protocols; D5W is standard); always verify Calvert formula calculation with capped CrCl (max 125 mL/min).
Pharmacist Patient Counselling Points:
- Dilute in 5% Dextrose (D5W — avoid chloride-containing solutions which accelerate degradation in long storage, though short-term 0.9% NaCl is used in some protocols; D5W is standard); always verify Calvert formula calculation with capped CrCl (max 125 mL/min).
- Report fever >=38.0°C (100.4°F) immediately (medical emergency: possible febrile neutropenia).
- Follow strict reproductive contraception and safe cytotoxic oral handling instructions.
Storage, Stability & Dispensing Safeguards: Dilute in 5% Dextrose (D5W — avoid chloride-containing solutions which accelerate degradation in long storage, though short-term 0.9% NaCl is used in some protocols; D5W is standard); always verify Calvert formula calculation with capped CrCl (max 125 mL/min).
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: National Cancer Grid (NCG) India Consensus Guidelines; NLEM 2022 Antineoplastic Section; Indian Pharmacopoeia (IP) & CDSCO Approved Oncology Prescribing Information.
Official Verification Portals: National Cancer Grid (NCG) India — Evidence-Based Oncology Guidelines • CDSCO — Central Drugs Standard Control Organization Approved Drug Data • Indian Pharmacopoeia Commission (IPC)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [ONC-10] Bleomycin Sulfate — Antitumour Antibiotic (G2/M Phase Specific) • Glycopeptide Radiom
- [ONC-12] Oxaliplatin — Platinum Alkylating-Like Agent • Third-Generation Diaminocyclohex
- [ONC-13] Docetaxel — Antimitotic Taxane (M-Phase Specific) • Semisynthetic Taxane Micr
- [ONC-14] Vincristine Sulfate — Vinca Alkaloid (M-Phase Specific) • Vinca Alkaloid Microtubule Po
